Ethicon’s ECHELON Powered Stapler with Gripping Surface Technology Published

Ethicon’s ECHELON Powered Stapler with Gripping Surface Technology (GST) reloads was associated with a lower rate of bleeding-related complications than Medtronic’s Signia Stapling System with Tri-Staple among patients undergoing laparoscopic sleeve gastrectomy for obesity, according to the first real-world evidence study comparing the two leading powered surgical stapling systems. The peer-reviewed study, which appears online in Medical Devices: Evidence and Research, was funded by Ethicon, part of the Johnson & Johnson Medical Devices Companies.

Ethicon has now sponsored six, large-scale, retrospective real-world studies on clinical outcomes associated with ECHELON Powered Staplers. The research, which spans four countries and more than 41,000 patients, showed a reduction in both bleeding complications and hospital costs when ECHELON Powered Staplers are used versus other leading surgical staplers.

In the latest study, researchers found bleeding complication rates were up to 73% lower in the ECHELON Powered Stapler with GST reloads group than they were in the Signia group (0.61% vs. 2.24%).1  The complication rate associated with ECHELON Powered Staplers was below the national average for the bariatric procedure, which previous studies have shown to range from 1.16% to 4.94%.2 While bleeding complications are not common, they can be life threatening.3

The study also found median total hospital costs were approximately 7% lower for the ECHELON Powered Stapler with GST reloads group4 – although the difference was not significant for mean total hospital costs. Differences between the two stapler groups for length of stay, operating room time and all-cause inpatient readmissions within 90 days were also not statistically significant.

The study authors, which included four bariatric surgeons from around the world, used the Premier Healthcare Database of U.S. hospital discharge records to identify and analyze the real-world outcomes of 982 inpatient sleeve gastrectomy patients (491 ECHELON Powered Stapler with GST and 491 Signia System with Tri-Staple) matched for patient and hospital/provider characteristics from a pool of 5,573 patients who had the procedure between March 2017 and December 2018.

“While the study demonstrated that ECHELON Powered Stapler with GST reloads was associated with lower hemostasis related complications, further analysis is required to determine why. What we do know is stapler selection in bariatric surgery could be very important. The differences in stapler design can correlate with outcomes and complications following bariatric surgery,” said lead study author Michael “Logan” Rawlins, MD***, a bariatric surgeon with the Allegheny Health Network Bariatric & Metabolic Institute in Pittsburgh, PA.

The study authors noted, “Whereas (ECHELON) GST stabilizes and controls tissue movement through a multi-stage compression, gripping surface technology, and surgeon-controlled power; Signia with Tri-Staple has more tissue movement through a single-stage compression, a stepped cartridge and device-controlled power, thus potentially having different tissue effects intra and postoperatively.”

The ECHELON Powered Stapler with GST reloads provides a better way to staple due to its gripping surface technology, 2-stage compression and ability to handle a broad range of tissue thicknesses. The ECHELON Powered Stapler with GST reloads delivered 4-times less tissue slippage and can accommodate the broadest range of tissue thicknesses compared to Medtronic staplers.5,6 It is the only surgical stapling brand backed by large-scale, real-world, peer-reviewed evidence.7

“Ethicon is committed to improving outcomes and reducing complication rates in surgery through an evidence-based approach to elevate standard of care. Our approach encompasses understanding of the disease state, impact of surgical techniques, science of device-tissue interaction, innovative stapler design and professional education,” said Sanjoy Roy, Director, Global Health Economics and Market Access, Ethicon, Inc. and a co-author of the study.


References

  1. Rawlins L, Johnson BH, Johnston SS, et al. Comparative Effectiveness Assessment of Two Powered Surgical Stapling Platforms in Laparoscopic Sleeve Gastrectomy: A Retrospective Matched Study. Medical Devices: Evidence and Research. 2020:13 195–204. doi: https://doi.org/10.2147/MDER.S256237. Analysis of hemostasis-related complication outcomes from 982 laparoscopic sleeve gastrectomy cases between March 1, 2017 and December 31, 2018 from Premier Healthcare Database (0.61% versus 2.24%, p=0.0012).
  2. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5339325/#:~:text=Discussion,the%20abdominal%20wall%20%5B12%5D.
  3. https://www.sages.org/meetings/annual-meeting/abstracts-archive/risk-factors-and-outcomes-for-bleeding-following-bariatric-surgery-results-from-the-metabolic-and-bariatric-surgery-accreditation-and-quality-improvement-program-mbsaqip/
  4. Rawlins L, Johnson BH, Johnston SS, et al. Comparative Effectiveness Assessment of Two Powered Surgical Stapling Platforms in Laparoscopic Sleeve Gastrectomy: A Retrospective Matched Study. Medical Devices: Evidence and Research. 2020:13 195–204. doi: https://doi.org/10.2147/MDER.S256237. Analysis of median total hospital cost outcomes from 982 laparoscopic sleeve gastrectomy cases between March 1, 2017 and December 31, 2018 from Premier Healthcare Database ($9,771 vs. $10,487, p=0.184)
  5. Benchtop testing in porcine stomach tissue.   Mean tissue movement from after clamping on tissue to after firing ECHELON FLEX™ Powered Plus Stapler (PSEE60A) and ECHELON Reload with GST vs ENDO GIA™ ULTRA Handle (EGIAUSTND) and Endo GIA™ Reload with Tri-Staple™ Technology at 3.3 and 4.0mm tissue thicknesses (3.3mm: GST60T 0.642mm vs EGIA60AMT 4.806mm p<0.001; 4.0mm: GST60T 0.654mm vs EGIA60AXT 5.116mm p<0.001).
  6. Comparison of the ECHELON FLEX™ GST System designed to accommodate a compressed tissue thickness range of 1.0mm to 4.0mm vs the Medtronic Tri-Staple portfolio intended for a thickness range of 0.75mm to 3.0mm (Medtronic literature, downloaded from Medtronic website on Nov 16, 2016).
  7. Based on literature search performed May 2019. Large-scale is defined as sample size greater than 3,500 cases.

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”
Exit mobile version